Search Job Title Only
Treasury & Bonds
View Full List
Dow Jones Industrial Average
Standard & Poors 500
NYSE COMPOSITE INDX
March 28, 2012 at 12:16 PM EDT
Roche Cuts the Price of Cancer Drugs in India – Under Pressure?
Last week, Roche said it would “significantly” reduce the price the company charges in India for two expensive biotech cancer drugs – Herceptin and MabThera (known as Rituxin in the US). The move came two weeks after India stripped Bayer of its exclusive license to market the cancer treatment Nexavar in India. India allowed a local company to produce Nexavar at a price of $172 per month, a 97% reduction from the $5,500 that Bayer charged. To most people, the two stories seem related, even though Roche would not say the implicit pressure from Indian authorities was responsible for its price reductions. More details.... Stock Symbols: (VX: ROG) (Xetra: BAY) Share this with colleagues: // //
Read More >>
Stock Market XML and JSON Data API
provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays.
Stock Market Holiday List
By accessing this page, you agree to the following
Terms and Conditions
Press Release Service
provided by PRConnect.
Stock quotes supplied by Six Financial
Bots go here